Effects of 15-deoxy-Δ12, 14 prostaglandin J2 and ciglitazone on human cancer cell cycle progression and death: The role of PPARγ

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 80-86

  Ferreira Silva, Valéria ^a   Rodrigues, Alice Cristina ^a   Hirata, Thiago Dominguez Crespo ^a   Hirabara, Sandro Massao ^a   Curi, Rui ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

15 d PGJ2; Apoptosis; Cancer cells; PPAR ; RNAi; Thiazolidinedione

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN U937; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; KNOCKOUT GENE; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA FRAGMENTATION; G2 PHASE; GENE EXPRESSION REGULATION; GENE SILENCING; HELA CELLS; HUMANS; JURKAT CELLS; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES; U937 CELLS;

EID: 37649001831     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.004     Document Type: Article

References (30)

1. Abe A., Kiriyama Y., Hirano M., Miura T., Kamiya H., Harashima H., and Tokumitsu Y. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur. J. Pharmacol. 436 (2002) 7-13
2. Chaffer C.L., Thomas D.M., Thompson E.W., and Williams E.D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6 (2006) 53
3. Chen F., and Harrison L.E. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell. Signal. 17 (2005) 809-816
4. Chen Y.C., Shen S.C., and Tsai S.H. Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim. Biophys. Acta 1743 (2005) 291-304
5. Chen Y., Jimenez A.R., and Medh J.D. Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim. Biophys. Acta 1759 (2006) 32-43
6. Clay C.E., Atsumi G.I., High K.P., and Chilton F.H. Early de novo gene expression is required for 15-deoxy-delta 12,14-prostaglandin J2-induced apoptosis in breast cancer cells. J. Biol. Chem. 276 (2001) 47131-47135
7. Clay C.E., Monjazeb A., Thorburn J., Chilton F.H., and High K.P. 15-deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J. Lipid Res. 43 (2002) 1818-1828
8. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet. Med. 16 (1999) 179-192
9. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
10. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272 (1997) 18779-18789
11. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5 (2004) 419-429
12. Harris S.G., and Phipps R.P. Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 105 (2002) 23-34
13. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
14. Kanunfre C.C., da Silva Freitas J.J., Pompeia C., Goncalves de Almeida D.C., Cury-Boaventura M.F., Verlengia R., and Curi R. Ciglitizone and 15d PGJ2 induce apoptosis in Jurkat and Raji cells. Int. Immunopharmacol. 4 (2004) 1171-1185
15. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771-774
16. Konopleva M., Elstner E., McQueen T.J., Tsao T., Sudarikov A., Hu W., Schober W.D., Wang R.Y., Chism D., Kornblau S.M., Younes A., Collins S.J., Koeffler H.P., and Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol. Cancer Ther. 3 (2004) 1249-1262
17. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
18. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
19. Li L., Tao J., Davaille J., Feral C., Mallat A., Rieusset J., Vidal H., and Lotersztajn S. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276 (2001) 38152-38158
20. Masuda T., Wada K., Nakajima A., Okura M., Kudo C., Kadowaki T., Kogo M., and Kamisaki Y. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin. Cancer Res. 11 (2005) 4012-4021
21. Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 61 (2001) 6213-6218
22. Ray D.M., Akbiyik F., and Phipps R.P. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J. Immunol. 177 (2006) 5068-5076
23. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
24. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
25. Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D.L., and Heneka M.T. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J. Leukoc. Biol. 75 (2004) 478-485
26. Shiau C.W., Yang C.C., Kulp S.K., Chen C.S., Huang J.W., and Chen C.S. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independentely of PPARgamma. Cancer Res. 65 (2005) 1561-1569
27. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4844-4849
28. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
29. Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G.M., and Catapano C.V. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8 (2006) 851-861
30. Weng J.R., Chen C.Y., Pinzone J.J., Ringel M.D., and Chen C.S. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer 13 (2006) 401-413